Answers are grounded in this paper and cite their sources.
Rationale Following an important increase in the number of patients treated with positive airway pressure (PAP) therapy in France, a new nationwide model combining telemonitoring and a pay-for-performance scheme was implemented in 2018. Objectives To provide a comprehensive overview of 5-year persistence and adherence to PAP therapy and healthcare utilization after the change in the PAP pathway and model. Methods This real-world cohort included adults from France started on PAP in 2019–2023. Data sources included provider records (including daily PAP data) and national claims data. Costs were evaluated from the national payer perspective. Results A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring. 58,116 patients had paired claims data. PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years. Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%). There was a dose-effect association between PAP adherence in the first 4 months and 5-year persistence. In the first year of treatment, on average, patients consulted with a general practitioner 6.66 times and with another medical specialist 2.53 times; over the same period home service providers delivered 4.0 interventions at home, 3.6 by phone and 2.8 masks. The number of provider interventions (logistic, educational and supportive) increased as adherence decreased. Mean yearly total cost per patient was €5,462: €1,526 (28%) for hospitalizations, €672 (12%) for disability pensions and sick leave benefits, €436 (8%) for the PAP device, consumables and service, and €415 (8%) for medical consultations. Conclusions The proportion of adherent patients at 5 years was high, partly driven by the early discontinuation of patients with low adherence. Alongside intensive medical follow-up, HSPs delivered interventions at greater intensity for patients with low adherence, consistent with the objective of the nationwide telemonitoring and pay-for-performance model. However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.
No takes yet. Share an insight, caveat, or question.
Baillieul et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: